drugset
drugset / Trial / NCT07587801

Vaccination Response Modulation With a Targeted Rapamycin Protocol Study

NCT07587801 ↗

Phase 2 Not yet recruiting 60 enrolled Central Adelaide Local Health Network Incorporated
RandomizedParallel-groupOpen-labelPrevention

Summary

This study will investigate dialysis recipients' responses to important vaccines. Research suggests that a medication commonly used by transplant recipients may improve vaccine responses. The investigators will be conducting a clinical trial to see whether a short course of low-dose Sirolimus improves the response to vaccination against respiratory syncytial virus (RSV) and influenza (flu) in patient with kidney disease over 60 years old who receive haemodialysis.

Timeline

Start
2026-05
Primary completion
2026-07
Completion
2026-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 2 mg Oral
Background Influenza Virus Vaccine Vaccine — —
Background RSVpreF Vaccine — —

Indications

No indication recorded.